• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    FibroBiologics, Inc. - Common Stock (NQ: FBLG )

    2.250 +0.220 (+10.84%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about FibroBiologics, Inc. - Common Stock

    FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
    Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care programs 
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics Engages Southern Star Research as CRO in Australia
    Southern Star Research will provide CRO services for FibroBiologics in Australia 
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics Files 2024 Second Quarter Report
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics to Present at JonesTrading Healthcare Summit 2024
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics Set to Join Russell 2000® Index
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics to Present at Extracellular Matrix Pharmacology Congress 2024
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics Announces 2024 Annual Meeting of Stockholders
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics Files 2024 First Quarter Report
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics to Present at the BIO International Convention 2024
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids
    Next-generation cell therapies to target chronic diseases 
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
    From Fibrobiologics, Inc.
    Via GlobeNewswire
    FibroBiologics (NASDAQ: FBLG) Shares Jump 88% After Announcing Preclinical Data During Presentation at 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases
    FibroBiologics (NASDAQ: FBLG) shares caught a notable bid during trading on Tuesday, February 13, 2024. The clinical-stage biotech company saw 
    Via Spotlight Growth
    Topics Intellectual Property
    Exposures Intellectual Property
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.